Modulation Of The Tumor Micro-Environment By Oncos-102 –
Experience From Several Types Of Cancer
• ONCOS-102 acts synergistically to reduce tumor volume with the
chemotherapy combination of pemetrexed and cisplatin (Pem/Cis),
which is the current standard of care in malignant pleural mesothelioma
• Demonstration that ONCOS-102 induces CD8+ T-cells specific to
the tumor associated antigen (TAA) mesothelin, which is typically
overexpressed in mesothelioma, as well as many other forms of cancer
Next_Generation_Cancer_Vaccine_Development_Summit___Event_Guide